MEET-AML
Personalising acute myologic leukaemia treatment using a new algorithm and integrating patient preferences in personal medicine.
Time and funding
- Period: 2020-01-01 – 2022-12-31
- Budget: 4,340,000 SEK
- Funder: Swedish Research Council
- Type of funding: Projektbidrag
Personalised cancer treatment & patient preferences
Patients suffering from acute myologic leukaemia (AML) respond very differently to available treatments. Now, researchers in the multidisciplinary project MEET-AML (funded by the Swedish Research Council) hope to be able to tailor treatment for individual patients with the aid of a new algorithm targeting vulnerabilities in cancerous cells using -omics-data.
Using a new algorithm and integrating patient preferences, researchers in Italy, Spain, France, Germany, Finland, and Sweden will spend 3 years developing new treatments for acute myologic leukaemia, a cancer type of cancer where personalised treatment has not previously been available.
But it’s not just the vulnerabilities in the leukaemia cells the researchers are interested in. MEET-AML will also develop ways of integrating patient preferences, what they want and how they make benefit-risk trade-offs, into the personalised treatment. Raising important questions of when and how to integrate patient preferences in medical decision-making.
Researchers from Uppsala University’s Centre for Research Ethics & Bioethics will perform quantitative and qualitative studies about AML-patients’ preferences in Finland, Germany and Italy.
Collaborators
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) srl, IRCCS, Italy
- Charité University Medicine Berlin, Germany
- University of Helsinki, Finland
- Inserm Délégation Régionale Nord Ouest, France
- University of Navarra, Spain
- Uppsala University's Centre for Research Ethics & Bioethics, Sweden
People in the project
Åsa Grauman
Researches how individuals perceive health risks and how we are affected by risk information, including through preference studies, with a focus on breast cancer, bowel cancer, precision medicine, and screening for rare diseases.
Jennifer Viberg Johansson
Associate professor in medical ethics, with a research focus on methods that measure people's preferences and how to balance preferences against other ethical values; artificial intelligence and digital health information.
